DE602006017331D1 - Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien - Google Patents

Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien

Info

Publication number
DE602006017331D1
DE602006017331D1 DE602006017331T DE602006017331T DE602006017331D1 DE 602006017331 D1 DE602006017331 D1 DE 602006017331D1 DE 602006017331 T DE602006017331 T DE 602006017331T DE 602006017331 T DE602006017331 T DE 602006017331T DE 602006017331 D1 DE602006017331 D1 DE 602006017331D1
Authority
DE
Germany
Prior art keywords
biologically active
bacteria
darm
supply
active substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602006017331T
Other languages
German (de)
English (en)
Inventor
Simon Carding
Mark Farrar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plant Bioscience Ltd
Original Assignee
University of Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds filed Critical University of Leeds
Publication of DE602006017331D1 publication Critical patent/DE602006017331D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602006017331T 2005-01-25 2006-01-24 Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien Expired - Lifetime DE602006017331D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501540.9A GB0501540D0 (en) 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria
PCT/GB2006/000222 WO2006079790A2 (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria

Publications (1)

Publication Number Publication Date
DE602006017331D1 true DE602006017331D1 (de) 2010-11-18

Family

ID=34259652

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006017331T Expired - Lifetime DE602006017331D1 (de) 2005-01-25 2006-01-24 Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien

Country Status (10)

Country Link
US (1) US7988961B2 (https=)
EP (1) EP1841875B1 (https=)
JP (1) JP4989490B2 (https=)
KR (1) KR101291960B1 (https=)
AT (1) ATE483811T1 (https=)
CA (1) CA2640343C (https=)
DE (1) DE602006017331D1 (https=)
ES (1) ES2353721T3 (https=)
GB (1) GB0501540D0 (https=)
WO (1) WO2006079790A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008317000B2 (en) * 2007-10-26 2014-10-23 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
EP2258844A1 (en) 2009-05-28 2010-12-08 Helmholtz Zentrum Für Infektionsforschung Tumour-specific bacterial promoter elements
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
WO2015095796A1 (en) 2013-12-20 2015-06-25 President And Fellows Of Harvard College An engineered genetic enteric sensor bacteria and uses thereof
US10610546B2 (en) 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
AU2015369627A1 (en) * 2014-12-22 2017-07-06 Massachusetts Institute Of Technology Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
BR112017018656B1 (pt) * 2015-03-02 2021-11-30 Synlogic, Inc Bactéria geneticamente modificada, composição farmaceuticamente aceitável compreendendo a dita bactéria e uso da dita composição para tratar ou prevenir uma doença ou condição associada à inflamação intestinal e/ou função da barreira intestinal comprometida
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017087580A1 (en) 2015-11-16 2017-05-26 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia
AU2017252409B2 (en) 2016-04-20 2023-08-24 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
WO2018112194A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
US11224624B2 (en) * 2017-02-14 2022-01-18 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior and disease
US20200268813A1 (en) * 2017-02-15 2020-08-27 President And Fellows Of Harvard College Modulation of host immune cell populations using gut microbiota
WO2018183685A1 (en) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
JP2020516318A (ja) * 2017-04-17 2020-06-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 操作された共生細菌及び使用方法
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
JP2022512380A (ja) 2018-12-10 2022-02-03 ノヴォム バイオテクノロジーズ，インコーポレイテッド 高シュウ酸尿症を治療するための方法及び組成物
CN115298308A (zh) 2020-03-20 2022-11-04 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569604A1 (en) 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
JP2003509046A (ja) * 1999-09-10 2003-03-11 イギリス国 組換え微生物
JP2001275680A (ja) * 2000-03-31 2001-10-09 Yakult Honsha Co Ltd β−１，３−キシラナーゼ遺伝子、該遺伝子を導入した微生物、及びβ−１，３−キシラナーゼの製造法
JP2003144200A (ja) * 2001-11-07 2003-05-20 Yakult Honsha Co Ltd バクテロイデスグループ細菌用プローブおよびこれを用いた検出方法

Also Published As

Publication number Publication date
KR101291960B1 (ko) 2013-08-09
EP1841875B1 (en) 2010-10-06
EP1841875A2 (en) 2007-10-10
WO2006079790A2 (en) 2006-08-03
JP4989490B2 (ja) 2012-08-01
KR20070108882A (ko) 2007-11-13
CA2640343C (en) 2014-01-14
CA2640343A1 (en) 2006-08-03
WO2006079790A3 (en) 2006-12-21
ES2353721T3 (es) 2011-03-04
US7988961B2 (en) 2011-08-02
ATE483811T1 (de) 2010-10-15
JP2008527988A (ja) 2008-07-31
GB0501540D0 (en) 2005-03-02
US20080131402A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
DE602006017331D1 (de) Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2534744T3 (es) Plasmina modificada de forma recombinante
PE20130593A1 (es) DOMINIOS DE FIBRONECTINA TIPO III A LA DECIMA (10Fn3) MODIFICADOS DE UNION A SEROALBUMINA
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
MY180672A (en) Ace2 polypeptide
BR112013010487A2 (pt) novos substratos de coelenterazina e métodos de uso
NZ596037A (en) Fgf21 mutants and uses thereof
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
MY159433A (en) Fibrous materials and compositions
MX2009013137A (es) Metodos para seleccionar polipeptidos resistentes a la proteasa.
EA201001883A1 (ru) Мутанты fgf21 и их применение
NZ596658A (en) Dig-10 insecticidal cry toxins
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
NO20076043L (no) Glucagon-lignende peptid-2 (GLP-2) analoger
EP2409988A3 (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
PE20120551A1 (es) Anticuerpos contra la angiopoyetina 2 humana
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
GB0514779D0 (en) Biological products
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
NO20082510L (no) En fremgangsmate for konsentrasjon av et polypeptid
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PLANT BIOSCIENCE LTD., NORWICH, NORFOLK, GB

8328 Change in the person/name/address of the agent

Representative=s name: PATENTANWAELTE FREISCHEM, 50677 KOELN